Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).
1 finding from 1 review
Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)
It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).
1 finding from 1 review
Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
All‐cause mortality assessed up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death · individuals with moderate or severe COVID‐19
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
All‐cause mortality up to 30 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes all‐cause mortality up to 30 days № of participants: 72 (1 RCT) compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).
1 finding from 1 review
RR 0.38 [0.13, 1.1]
Studies not reported
Very low
Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found